Raymond Deshaies, Ph.D., is senior vice president, Global Research.

Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute.

In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Therapeutics.

Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the American Academy of Arts and Sciences and National Academy of Sciences. In 2022, Fierce Pharma named Deshaies as one of the most influential people in biopharma. He received the 2023 Jacob and Louise Gabbay Award in Biotechnology and Medicine along with Yale University professor, Craig Crews, for their pioneering work on PROTACs, or proteolysis targeting chimeras.